MedTrace Logo

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

NCT03023358 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2017-01-18

No results posted yet for this study

Summary

The prognosis for Peripheral T cell lymphomas (PTCL) remains poor in comparison to B cell NHL. This is largely due to lower response rates and less durable responses to standard combination chemotherapy regimens such as CHOP. Whether CDOP plus Chidamide can improve the prognosis for PTCL.

Conditions

  • Peripheral T Cell Lymphoma

Interventions

DRUG

chidamide

30mg po twice a week

DRUG

cyclophosphamide

750mg/m2 iv on day 1

DRUG

liposomal doxorubicin

30mg/m2 iv on day 1

DRUG

vincristine

1.4mg/m2 iv on day 1

DRUG

prednisone

100mg/d po on day 1-5

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Ru Feng, M.D. · Department of Hematology Nanfang Hospital, The Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023358 on ClinicalTrials.gov